Bispecific Antibodies Explained: Two Targets, One Molecule

One Molecule, Two Jobs

A conventional antibody binds a single target. A bispecific antibody is engineered to bind two different targets at once — an innovation that unlocks mechanisms a single-target antibody can't achieve. Bispecifics have become a major modality, especially in oncology, and understanding how they work clarifies why they compete with — and sometimes complement — ADCs and CAR-T.

The Marquee Use: T-Cell Engagers

The most prominent bispecific design is the T-cell engager. One arm of the antibody grabs a protein on a cancer cell; the other grabs a protein on a T cell (typically CD3). By physically bridging the two, the bispecific drags the patient's own immune cells directly onto the tumor and triggers them to kill it.

This mechanism is conceptually similar to CAR-T's goal — directing T cells against cancer — but achieved very differently:

• Off-the-shelf. A bispecific is a manufactured antibody given as a drug, not a bespoke cell product made for each patient. That sidesteps CAR-T's complex, costly, personalized manufacturing.
• Easier administration. It can often be given more like a conventional biologic, broadening where and to whom it can be delivered.
• Controllable dosing. Unlike a living CAR-T product, a bispecific can be stopped, which can help manage toxicity.

The Trade-offs

Bispecifics share some of the same risks as other T-cell-directed therapies and add their own:

• Cytokine release syndrome (CRS) and related toxicities can occur, as with CAR-T, because both activate T cells against tumor.
• Short half-life in some designs requires frequent or continuous dosing, though engineering has improved durability.
• Target selection is everything — the tumor antigen must be selective enough to avoid serious on-target, off-tumor effects.

Beyond T-Cell Engagers

Bispecifics aren't only T-cell engagers. Other designs:

• Block two signaling pathways simultaneously to overcome resistance.
• Combine targeting and immune modulation in one molecule.
• Bridge an immune cell other than a T cell to a target.

The platform nature of bispecific engineering means a company with strong antibody-engineering capabilities can generate many distinct programs — a source of pipeline optionality and valuation premium.

How Investors Should Compare Modalities

In oncology, ADCs, CAR-T, and bispecifics increasingly compete for the same indications, so part of due diligence is understanding the relative trade-offs:

• ADCs deliver a toxic payload to antigen-expressing cells.
• CAR-T offers potentially deep, durable responses but with bespoke manufacturing and serious toxicity.
• Bispecifics offer off-the-shelf convenience and controllable dosing, often trading some response depth for accessibility.

No modality is universally superior; the right question is which fits a given disease, patient population, and competitive setting.

What Investors Should Watch

• Efficacy vs. the relevant standard of care and competing modalities in the same indication.
• Toxicity management, especially CRS, and whether it's controllable in practice.
• Dosing convenience and durability — a meaningful commercial differentiator.
• Platform productivity — is the company turning its engineering into multiple advancing programs?

Applying It

Bispecific antibodies bring much of the immune-directed power of cell therapy in an off-the-shelf format, which is reshaping competitive dynamics in oncology. Evaluate a bispecific on its efficacy relative to alternatives, its toxicity profile, its dosing convenience, and the breadth of the platform behind it.

Track bispecific program readouts on the Phase 3 calendar and FDA decisions, and compare competing modalities across company pages. In modern oncology, the modality is part of the thesis — and bispecifics have earned their place in the mix.